Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.3230
+0.0332 (11.46%)
At close: Apr 21, 2025, 4:00 PM
0.3230
0.00 (0.00%)
Pre-market: Apr 22, 2025, 4:13 AM EDT
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$4,704,668
Market Cap
10.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
RLMD News
- 7 days ago - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GlobeNewsWire
- 7 days ago - Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GlobeNewsWire
- 25 days ago - Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - GlobeNewsWire
- 26 days ago - Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - GlobeNewsWire
- 27 days ago - Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - GlobeNewsWire
- 2 months ago - Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - GlobeNewsWire
- 4 months ago - Relmada discontinues late-stage trials for depression drug, explores sale - Reuters